Joseph R. Bertino, M.D.
Affiliations: | Weill Cornell Medical College, New York, NY, United States | ||
| 1961-1987 | Yale University School of Medicine, New Haven, CT |
Area:
Biochemistry, Molecular Biology, PharmacologyWebsite:
https://www.aacr.org/professionals/membership/in-memoriam/joseph-r-bertino/Google:
"Joseph Bertino"Bio:
(1930 - 2021)
https://www.bcrf.org/blog/joseph-bertino-bcrf-tribute-2021/
https://www.healio.com/news/hematology-oncology/20120325/joseph-r-bertino-md-history-buff-and-gourmand
https://www.legacy.com/us/obituaries/nhregister/name/joseph-bertino-obituary?id=30338690
https://cancerhistoryproject.com/people/joseph-r-bertino-md-leukemia-and-lymphoma-pioneer/
Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Clement Alfred Finch | post-doc | University of Washington (Physiology Academic Tree) | |
| Frank M. Huennekens | post-doc | University of Washington | |
| Arnold D. Welch | research scientist | 1961 | Yale |
Children
Sign in to add trainee| John P. Perkins | grad student | 1966 | Yale |
| Gina M. Capiaux | grad student | 2002 | Weill Cornell Medical College |
| Pellegrino G. Magro | grad student | 2003 | Weill Cornell Medical College |
| Angelo J. Russo | grad student | 2004 | Weill Cornell Medical College |
| Nancy E. Skacel | grad student | 2004 | Weill Cornell Medical College |
| Edwin C. Cadman | post-doc | 1976 | Yale School of Medicine (Cell Biology Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin Z, Lin SY, Xie P, et al. (2020) Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy. Scientific Reports. 10: 3015 |
| Rather GM, Szekely Z, Bertino JR. (2020) Abstract 2212: An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer Immunology. 80: 2212-2212 |
| Rather GM, Lin SY, Lin H, et al. (2019) A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma. Frontiers in Oncology. 9: 258 |
| Goldfinger M, Xu M, Bertino JR, et al. (2019) Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia |
| Chaturvedi S, Bertino JR. (2019) Methods to Study the Role of Methionine-Restricted Diet and Methioninase in Cancer Growth Control. Methods in Molecular Biology (Clifton, N.J.). 1866: 1-12 |
| Rather GM, Anyanwu M, Kerrigan JE, et al. (2019) Abstract 5213: A modified L-penetratin peptide targeting e2f-1, 2 and 3 is effective in combination with cisplatin or pemetrexed against prostate and lung cancer cell lines Cancer Research. 79: 5213-5213 |
| Shaik T, Rather GM, Bansal N, et al. (2018) Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget. 9: 33249-33257 |
| Rather GM, Lin SY, Lin H, et al. (2018) Activated matriptase as a target to treat breast cancer with a drug conjugate. Oncotarget. 9: 25983-25992 |
| Chaturvedi S, Hoffman RM, Bertino JR. (2018) Exploiting methionine restriction for cancer treatment. Biochemical Pharmacology. 154: 170-173 |
| Wagner J, Kline CL, Zhou L, et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation |